Last updated 2026-07-26
- Raised $1M Undisclosed Round led by Peregrine Ventures, Feb 2025
- Raised $800k grant, Jan 2023
- Raised $2.9M grant led by SIBF, Aug 2022
Total raised
$4.7M
Last: Undisclosed Round 2025-02
Stage
Seed
Founded
2019
Headcount
2
HQ
Petah Tikva, Israel
Sector
Health Tech & Life Sciences
About
Xerient is focused on unmet needs in cancer treatment, particularly in abdominal and gastrointestinal cancers. The company is pursuing the development of novel therapeutic technology that can dramatically improve the survival of these patients. Xerient is introducing a portfolio of products that will address hard-to-treat cancers in the abdominal/GI area, beginning with solutions for pancreatic cancer. They aim to make radiotherapy available for pancreatic cancer patients by introducing protection prior to applying radiation, repurposing an FDA-approved drug for oral administration.
Funding history · 3 rounds · $4.7M total
3 events/rounds · $4.7M Total Funding: $1.0M in Private Equity
Feb 2025
Undisclosed Round
$1.0M
pitchbook.com
Jan 2023
Cancer Prevention and Research Institute of Texas (CPRIT)
Aug 2022
★ SIBF★ and 2 more investors★ Cancer Prevention and Research Institute of Texas
Headcount over time
2 employees (2026-09) · 1 point
Offices
Petah Tikva, Israel · HQ / main office
Q&A
- What is Xerient's primary focus?
- Xerient is focused on developing novel therapeutics and diagnostic technologies for abdominal and gastrointestinal cancers, with a particular emphasis on pancreatic cancer.
- When was Xerient founded?
- Xerient was founded in May 2019.
- What is Xerient's total funding raised to date?
- Xerient has raised a total of $5,030,000 USD.
- Which organization provided a grant to Xerient in January 2023?
- In January 2023, Xerient received a grant of $2,930,000 USD from the BIRD Foundation.
- Who are the co-founders of Xerient?
- The co-founders of Xerient are Guy Yachin, Dr. Michael Shtein, and Cullen Taniguchi.
Team · 11
Guy Yachin
Founder · Co-Founder & CEO
Dr. Michael Shtein
Founder · Co-Founder & CSO
Cullen Taniguchi
Founder · Co-Founder
Dr. Ethan Ludmir
CMO (Interim)
Dr. Jessica Molkentine
Pre-clinical Director
Robbin Frnka
Clinical Director
Jeanne Jones
Clinical Project Manager
Danit Licht
Formulation Director
Guy Hoffman
Director
Eyal Lifschitz
Director
Doron Eldar
Director
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Highlights
1 Patents
Tags
gastroenterologycancerpharmaceuticalscancer-therapy
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | xerient.net/ |
|---|---|
| linkedin.com/company/56424827 |
Identifiers & details
| Legal name | XERIENT PHARMA LTD |
|---|---|
| Founded | 2019-5 |
| Employees (exact) | 2 |
Radar intelligence
Patents
| EPO | 3 |
|---|
Web history (Wayback)
| Domain | xerient.net |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516031630 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2019-05-28 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 1 — other (1) |
| Registered address | עין גדי 17 באר שבע |
Recent registry events
| Date | Event |
|---|---|
| 2025-11-11 | עדכון כתובת ו/או מען דיגיטלי |